Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242446 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04242446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04242446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
February 19, 2020
Completion date
February 19, 2023
Enrollment
505 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa